Abstract 461P
Background
Lung cancer is the leading cause of cancer deaths worldwide including in India. Around 80% of these are Non Small Cell Lung Cancers (NSCLC) detected in advanced stages where surgical resection is not an option and locally advanced stage patients are treated with concurrent chemoradiotherapy.
Methods
A total of 90 patients of NSCLC Stages IIIA and IIIB participated in the study conducted over the last eighteen months. They were randomized and distributed between two arms in 1:1 ratio. Their pre-treatment Pulmonary Function Tests were recorded. Participants in Arm A underwent 30 minutes of yoga session daily besides standard fractionation radiotherapy with concurrent weekly chemotherapy. Participants in Arm B received the same schedule of concurrent chemoradiotherapy but without the daily yoga session. Their post-treatment Pulmonary Function Tests were recorded at six weeks post completion of chemoradiotherapy and compared with pre-treatment values.
Results
21 participants in Arm A recorded positive changes in their FEV1 values, compared to just 3 patients in Arm B (p=0.0002), suggesting daily yoga sessions during treatment can actually help in improvement of lung function among locally advanced NSCLC patients.
Conclusions
Further multi-institutional studies with more participants should be encouraged and yoga be more maistreamed and formally incoporated into standard therapeutic regimens for the management of locally advanced non small cell lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract